Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus

Clinical Microbiology and Infection

Volumn 8, Issue 12, 2002, Pages 781-790

  Sierra, J M ^a   Marco, F ^a   Ruiz, J ^a   Jimenez de Anta M T ^a   Vila, J ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Fluoroquinolones; Resistance; S. aureus

Indexed keywords

BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GENE PRODUCT; LEVOFLOXACIN; METICILLIN; MULTIDRUG RESISTANCE PROTEIN; NORFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DRUG CONTRAINDICATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC EPIDEMIOLOGY; MARKER GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; RESTRICTION MAPPING; SEQUENCE HOMOLOGY;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0036936993     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00400.x     Document Type: Article

References (40)

1. Waldvogel FA. Staphylococcus aureus (including toxic syndrome). In: Mandell GL, Douglas RG, Bennet JE, eds. Principles and practices of infectious diseases. New York: Churchill Livingston, 1990: 1489-510.
2. Gahin-Hausen B, Joogard P, Arpi M. In vitro activity of ciprofloxacin against methicillin-sensitive and methicillin-resistant staphylococci. Eur J Clin Microbiol 1987; 6: 581-4.
3. Aldridge KE, Janney A, Saunders CV. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin and other β-lactam antibiotics against clinical isolates of methicillin resistant Staphylococcus aureus from various geographical locations. Antimicrob Agents Chemother 1985; 28: 634-8.
4. Wolfson JS, Hooper DC. The fluoroquinolones: structure, mechanisms of actions and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581-6.
5. Fass RJ. Treatment of skin and soft tissue infections with ciprofloxacin. J Antimicrob Chemother 1986; 18(suppl D): 153-7.
6. Humphryes H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet 1985; ii: 383.
7. Mulligan ME, Ruane PJ, Johnson L et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med 1987; 82(suppl 4): 215-19.
8. Thornsberry C. Susceptibility of clinical isolates to ciprofloxacin in the United States. Infection 1994; 22(suppl 2): 580-9.
9. Chow JW, Sorkin M, Goetz A, Yu VL. Staphylococcal infections in the hemodialysis unit: prevention using infection control principles. Infect Control Hosp Epidemiol 1988; 12: 531-3.
10. Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JI. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1997; 74: 4772-6.
11. Peng H, Marians KJ. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure and subunit interactions. J Biol Chem 1993; 268: 24481-90.
12. Sugino A, Peebles CL, Krenzer KN, Cozarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 1977; 74: 4767-71.
13. Ferrero LB, Cameron B, Manse B et al. Cloning and primary structure of S. aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641-53.
14. Ng EY, Truksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in S. aureus. Antimicrob Agents Chemother 1996; 40: 1881-8.
15. Ferrero LB, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in a stepwise-selected ciprofloxacin-resistant mutant of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8.
16. Gostwitz JJ, Willard KE, Fasching CE, Peterson LR. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant S. aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother 1992; 36: 1166-9.
17. Hopewell R, Oram M, Briesewitz R, Fisher LM. DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance. J Bacteriol 1990; 172: 3481-4.
18. Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 2014-23.
19. Sreedharan S, Oram M, Jensen B, Peterson LR, Fisher LM. DNA gyrase A mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J Bacteriol 1990; 172: 7260-2.
20. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus nor A gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942-9.
21. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 41: 2733-7.
22. Kaatz GW, Seo SM. Mechanism of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1997; 37: 1086-94.
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that growth aerobically. M7-A4. Villanova, Pa: NCCLS, 1998.
24. Gautom RK. Rapid pulsed field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other Gram-negative organisms in 1 day. J Clin Microbiol 1997: 35: 2977-80.
25. Abonkasm AG, Bun-Hoi AY, Solh NU, Morvan A, Acar JF. Epidemiological study of Staphylococcus aureus resistance to new quinolones in a university hospital. J Hosp Infect 1991; 17: 25-33.
26. Harnet N, Brown S, Krishan C. Emergence of quinolone resistance among clinical isolates of methicillin-resistant S. aureus in Ontario, Canada. Antimicrob Agents Chemother 1991; 35: 1911-13.
27. Shalit I, Berger SA, Gorea A, Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolated in a general hospital. Antimicrob Agents Chemother 1989; 33: 593-4.
28. Ruiz J, Gómez J, Navia MM et al. Elevada frecuencia de resistencia a ácido nalidíxico y susceptibilidad a ciprofloxacino entre cepas clínicas de Enterobacteriaceae. Mecanismos e implicaciones clínicas [abstract 615]. In: Program and abstracts of the IX Congreso de la Sociedad Española de Enfermedades Infecciosas Y Microbiología Clínica, Santiago de Compostela. Barcelona: Doyma, 2000: 188.
29. Conrad S, Oethinger M, Kaifel K, Klotz G, Marre R, Kern WV. gyrA mutations in high level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother 1996; 38: 443-5.
30. Vila J, Ruiz J, Goñi P, Jimenez de Anta MT. Detection of mutations in parC in quinolone-resistant isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 491-3.
31. Vila J, Ruiz J, Marco F et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and minimal inhibitory concentration. Agents Chemother 1994; 38: 2477-9.
32. Ince D, Hooper DC. Mechanisms and frequency of resistance to premafloxacin in S. aureus: novel mutations suggest novel drug interactions. Antimicrob Agents Chemother 2000; 44: 3344-50.
33. Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in E. coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 2001; 45: 1467-72.
34. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High-level flouroquinolone-resistant clinical isolates of E. coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother 2000; 44: 3441-3.
35. Kern WV, Oethinger M, Jellen-Ritter AS, Levy SB. Non-target gene mutations in the development of fluoroquinolone resistance in E. coli. Antimicrob Agents Chemother 2000; 44: 814-20.
36. Ruiz J, Sierra JM, Jiménez de Anta MT, Vila J. Characterization of in vitro obtained sparfloxacin-resistant mutants of Staphylococcus aureus. Int J Antimicrob Chemother 2001; 18(2): 107-12.
37. Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999; 26: 281-7.
38. Sierra JM, Ruiz J, Jimenez de Anta MT, Vila J. Prevalence of two different genes encoding NorA in 23 clinical strains of Staphylococcus aureus. J Antimicrob Chemother 2000; 46: 145-6.
39. Kaatz GW, Seo S, O'Brien L, Wahiduzzman M, Foster TJ. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1404-6.
40. Fournier B, Aras R, Hooper DC. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J Bacteriol 2000; 182: 664-71.